Want to see KMTS full AI Analyst Report?
KMTS Stock Chart & Stats
$25.73
$1.80(8.55%)
At close: 4:00 PM EDT
$25.73
$1.80(8.55%)
Day’s Range― - ―
52-Week Range$15.82 - $30.00
Previous CloseN/A
Volume51.18K
Average Volume (3M)291.76K
Market Cap
$1.47B
Enterprise Value$1.06K
Total Cash (Recent Filing)$196.43M
Total Debt (Recent Filing)$46.79M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Sep 14, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.42
Shares Outstanding58,603,123
10 Day Avg. Volume248,739
30 Day Avg. Volume291,761
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.66
Price to Sales (P/S)12.72
P/FCF Ratio-10.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.00Price Target Upside16.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.3
Revenue Forecast (FY)$137.02M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Commercial ExpansionRapid revenue growth is supported by prescription gains, deeper penetration of existing accounts, new account activation and an expanding sales footprint. If execution continues, these channels can provide a durable foundation for broader adoption and scale.
Sustained Gross-margin ExpansionConsistent margin improvement indicates strengthening unit economics as revenue scales, collections improve and revenue-per-fit increases. Management’s longer-term 70%+ target could materially improve operating leverage, provided commercial investments convert into lasting volume.
Clinical Evidence And Product DifferentiationLarge-scale real-world evidence can strengthen physician confidence, support guideline influence and improve adoption of Kestra’s wearable cardiac protection technology. The enhanced detection algorithm may further differentiate the product by reducing false alarms.
Bears Say
Large Ongoing Operating LossesThe company has not yet demonstrated a sustainable path to profitability despite strong growth. Persistent operating losses could delay self-funding, require additional capital and leave earnings highly sensitive to the pace of revenue growth and expense control.
Heavy Cash Burn And Funding RiskNegative operating and free cash flow shows that growth currently consumes substantial capital. Liquidity provides time to execute, but continued losses could increase reliance on debt or equity financing and raise dilution or refinancing risk if cash burn remains elevated.
High Investment And Execution RiskCommercial expansion and RCM investment may support future scale, but the sharp expense increase raises the execution hurdle. Modest conversion improvement and roughly six-month new-representative ramp times could delay operating leverage and create sustained cost pressure.
Kestra Medical Technologies Ltd. News
KMTS FAQ
What was Kestra Medical Technologies Ltd.’s price range in the past 12 months?
Kestra Medical Technologies Ltd. lowest stock price was $15.82 and its highest was $30.00 in the past 12 months.
What is Kestra Medical Technologies Ltd.’s market cap?
Kestra Medical Technologies Ltd.’s market cap is $1.47B.
When is Kestra Medical Technologies Ltd.’s upcoming earnings report date?
Kestra Medical Technologies Ltd.’s upcoming earnings report date is Sep 14, 2026 which is in 10 days.
How were Kestra Medical Technologies Ltd.’s earnings last quarter?
Kestra Medical Technologies Ltd. released its earnings results on Jul 14, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.08.
Is Kestra Medical Technologies Ltd. overvalued?
According to Wall Street analysts Kestra Medical Technologies Ltd.’s price is currently Undervalued.
Does Kestra Medical Technologies Ltd. pay dividends?
Kestra Medical Technologies Ltd. does not currently pay dividends.
What is Kestra Medical Technologies Ltd.’s EPS estimate?
Kestra Medical Technologies Ltd.’s EPS estimate is -0.62.
How many shares outstanding does Kestra Medical Technologies Ltd. have?
Kestra Medical Technologies Ltd. has 58,603,123 shares outstanding.
What happened to Kestra Medical Technologies Ltd.’s price movement after its last earnings report?
Kestra Medical Technologies Ltd. reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went up 1.799%.
Which hedge fund is a major shareholder of Kestra Medical Technologies Ltd.?
Currently, no hedge funds are holding shares in KMTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kestra Medical Technologies Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (16.60% Upside)
$30.00 (16.60% Upside)
Blogger Sentiment
Neutral
KMTS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kestra Medical Technologies Ltd.
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
KMTS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized robust top-line momentum (66% Q4 revenue growth, 59% FY growth), meaningful gross margin expansion (10+ percentage points QoQ/Yoy improvements), strong clinical validation (ACE-PAS study and publication), and reinforced liquidity via a $200M term loan — all supportive of durable long-term growth. Offsetting these positives are ongoing negative adjusted EBITDA, elevated operating investments (material increases in operating expense excluding nonrecurring items), and short-term phasing risks from rapid hiring and rep ramp-up. Management framed the expense growth as deliberate investment to capture a large underpenetrated market and expects operating leverage to improve over the next several years.View all KMTS earnings summariesKMTS Stock 12 Month Forecast
Average Price Target
$30.00
▲(16.60% Upside)
Technical Analysis
Ownership Overview
47.84% Insiders
26.37% Mutual Funds
4.75% Other Institutional Investors
15.07% Public Companies and
Individual Investors